<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690584</url>
  </required_header>
  <id_info>
    <org_study_id>2015/1456</org_study_id>
    <nct_id>NCT02690584</nct_id>
  </id_info>
  <brief_title>Metacognitive Therapy for Post-concussive Symptoms After Mild Traumatic Brain Injury</brief_title>
  <official_title>Metacognitive Therapy for Post-concussive Symptoms After Mild Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open trial is to investigate the feasibility, acceptability, and effect&#xD;
      of metacognitive therapy in patients with prolonged post-concussive symptoms after mild&#xD;
      traumatic brain injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptoms assessed by Rivermead Post Concussion Symptoms Questionnaire</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after completed therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conners CPT-III</measure>
    <time_frame>2 pre-treatment baseline measures, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-KEFS Trail Making Test</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color-Word Interference Test</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-KEFS Verbal Fluency</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modality Test</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory-Adult version (BRIEF-A)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The metacognitive beliefs questionnaire (MCQ-30)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue questionnaire (FQ)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inventory of Interpersonal Problems 64 (IIP-64)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue severity scale (FSS)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resilience scale for Adults (RSA)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth sleepiness scale (ESS)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia severity Index (ISI)</measure>
    <time_frame>baseline, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>3 pre-treatment baseline measures, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Inventory (BAI)</measure>
    <time_frame>3 pre-treatment baseline measures, immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Attention Syndrome (CAS-1)</measure>
    <time_frame>3 pre-treatment baseline measures, session to session (10 sessions), immediately after last therapy session, 10 weeks after completed therapy, 6 months after therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Brain Injuries</condition>
  <condition>Post-Concussive Symptom</condition>
  <condition>Post-Concussive Syndrome</condition>
  <arm_group>
    <arm_group_label>Metacognitive therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metacognitive therapy, one 45-60 min session weekly during 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Metacognitive therapy</intervention_name>
    <arm_group_label>Metacognitive therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with prolonged recovery after mild TBI (GCS &gt;12) will be recruited to our study if&#xD;
        they have post concussive symptoms &gt; 6 months after injury.&#xD;
&#xD;
        Patients will be recruited from an ongoing cohort study investigating mild and moderate TBI&#xD;
        at St. Olavs Hospital and Trondheim Municipality Emergency Clinic, and in addition (as of&#xD;
        October 2017) among TBI patients at St Olavs Hospital who were not included in the cohort&#xD;
        study.&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          -  Aged â‰¥between 16 and &lt; 60 years&#xD;
&#xD;
          -  Have sustained a traumatic brain injury&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Severe TBI (GCS score 8 or less)&#xD;
&#xD;
          -  Non fluency in Norwegian&#xD;
&#xD;
          -  Living outside of Norway&#xD;
&#xD;
          -  Major other trauma with high risk of disability lasting more than 3 months.&#xD;
&#xD;
          -  Major incidental intracranial findings in acute MRI e.g. cyst, tumor, malformation,&#xD;
             infarctions.&#xD;
&#xD;
          -  Severe psychiatric, neurological or medical disease, including: Psychotic disorders,&#xD;
             bipolar disorder, ongoing severe depressive episode&#xD;
&#xD;
               -  Personality disorders affecting adherence to the research protocol&#xD;
&#xD;
               -  Alcohol/drug abuse affecting adherence to the research protocol&#xD;
&#xD;
               -  Mental retardation, autism or other severe developmental disorders&#xD;
&#xD;
               -  Prior complicated mild, moderate or severe TBI&#xD;
&#xD;
               -  Stroke or other acquired brain injuries&#xD;
&#xD;
               -  Progressive neurological disorders (e.g. Parkinson's disease, MS)&#xD;
&#xD;
               -  Advanced cancer, heart- or respiratory disease or other somatic diseases that&#xD;
                  interfere with function.&#xD;
&#xD;
               -  Major other trauma e.g. spinal cord injury&#xD;
&#xD;
        In addition to exclusion criteria already employed in the cohort study, patients with&#xD;
        co-occurring psychiatric disorders that necessitate referral to specific treatment&#xD;
        according to existing guidelines will be excluded from the current intervention study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magne Arve Flaten, phd</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Olsen</last_name>
    <email>alexander.olsen@ntnu.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Psykologisk Institutt, Dragvoll</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Olsen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psychotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Post-Concussion Syndrome</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

